ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”

About this update from Immunitybio, Inc.

[{"type":"text","content":" CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of “The 100 Most Influential People in Oncology in 2025.” Soon-Shiong is the company’s Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and is a global thought leader in advancing the goal of a cancer-free society.\n\n\nOn its website announcing the honor, OncoDaily highlighted Soon-Shiong’s extensive scientific and research accomplishments, noting that The 100 Most Influential People in Oncology in 2025 recognizes changemakers in cancer care who have helped shape current oncology practice and continue to drive innovation across research, patient outcomes, advocacy, philanthropy, leadership, and education.\n\n\nOncoDaily, the “Voice of Oncology,” is a respected global source of news and information about developments in oncology, whose editorial staff and advisory board is comprised of leading academics, researchers and physicians specializing in cancer. Its annual Influential People list highlights individuals whose work is shaping oncology through clinical leadership, scientific innovation, education, advocacy, and philanthropy.\n\n\n“Dr. Soon-Shiong has earned this honor in recognition of his lifelong commitment to science, medicine, and patient care, a commitment that inspires our team and our partners every day,” said Richard Adcock, President and CEO of ImmunityBio. “His ideas and leadership are a driving force powering our mission to bring transformative therapies to people living with cancer and other serious diseases.”\n\n\nAbout ImmunityBio\n\n\nImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms t...

More updates from Immunitybio, Inc.